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We thank Moser for his comments [1] on the paper [2] 
we published in a previous issue of Arthritis Research & 
Th  erapy. To dispel any concerns about the proper use of 
the product, the autologous conditioned serum (ACS) in 
this study was prepared in a GMP (good manufacturing 
practice) facility in strict accordance with the guidelines 
supplied by the manufacturer (Orthogen, Düsseldorf, 
Germany) and was injected six times at 3-day intervals in 
accordance with the instructions given. As recom-
mended, immediately before injection of ACS, synovial 
ﬂ  uid was carefully aspirated to minimize ACS dilution. 
Th  is synovial ﬂ  uid was used to determine the cytokine 
levels before and during ACS treatment. We showed that, 
3 days after injection, cytokine levels were at baseline and 
had no secondary eﬀ  ects on other cyto  kines. Th  is  ﬁ  nding 
is not in conﬂ  ict with that of Darabos and colleagues [3], 
whose publication is cited by Moser; upon careful read-
ing of that publication, none of the eﬀ  ects of ACS injec-
tion, including the alleged decrease in synovial ﬂ  uid 
levels of interleukin-1 (IL-1), turned out to be statistically 
signiﬁ  cant.
We certainly agree with Moser that in vitro and in vivo
studies should be well controlled. However, in the case of 
ACS, the use of an autologous product is not required; 
this autologous product is devoid of cells, which are the 
only factors capable of evoking an immune response 
upon transfer of human materials to human recipients. 
We have used unconditioned serum as controls in our in 
vitro studies because serum in general seems to be more 
amenable to cartilage health than either saline or the 
synovial ﬂ  uid the tissue is exposed to in vivo [4]. In this 
setup, we could not demonstrate any eﬀ  ect of condition-
ing the serum. Th  e observation that IL-1 and tumor 
necrosis factor-alpha levels were upregulated in ACS, in 
contrast to the levels found previously upon characteri-
zation of ACS, may be due to the use of healthy subjects 
in the latter case, whereas we characterized the ACS 
prepared from osteoarthritis (OA) patients, the intended 
target population. Blood from OA patients was recently 
shown to contain cytokine proﬁ  les diﬀ  erent from those 
of healthy subjects, suggesting a diﬀ  erential  immune 
status [5].
Unconditioned serum, despite being the best control 
for ACS, has never been used in any in vivo study or 
clinical trial. Until now, the trials carried out with ACS 
have either used saline [6] or compared ACS with other 
treatments. However, the number of injections per 
treatment type was always dissimilar in these latter trials. 
For example, in the OA trial carried out by Baltzer and 
colleagues [7], six injections of ACS yielded more clinical 
improvement than three injections of hyaluronic acid, 
but the eﬀ  ect of multiple lavage sessions removing pro-
inﬂ   ammatory cytokines present in the synovial ﬂ  uid 
cannot be ruled out here. In addition, concerns about the 
blinding of the patients to their treatment may be raised. 
In particular, in OA, more invasive treatment shows a 
stronger placebo eﬀ  ect than non-invasive therapies do 
[8].
It is questionable whether ACS has any positive eﬀ  ects 
with regard to in vitro and in vivo chondroprotection and 
clinical outcome. Th   is notion is further corroborated by 
the fact that ACS therapy (Orthokine; Orthogen), to our 
knowledge, is not registered in any European country and 
that its ‘wide use’ is limited to clinical trials and some 
private clinics. We would encourage investigators to set  © 2010 BioMed Central Ltd
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© 2010 BioMed Central Ltdup ACS-based randomized controlled trials with full 
patient and observer blinding and with unconditioned 
serum as control in order to provide a ﬁ  nal answer to 
whether this treatment merits registration.
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